These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24472300)

  • 1. Frequent POLE1 p.S297F mutation in Chinese patients with ovarian endometrioid carcinoma.
    Zou Y; Liu FY; Liu H; Wang F; Li W; Huang MZ; Huang Y; Yuan XQ; Xu XY; Huang OP; He M
    Mutat Res; 2014 Mar; 761():49-52. PubMed ID: 24472300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.
    Wang F; Zou Y; Liu FY; Yu XH; Huang H; Zhang N; Qi YY; Liu RF; Liu XY; Chen J; Huang OP; He M
    Mol Med Rep; 2013 Jun; 7(6):1826-30. PubMed ID: 23588898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
    Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
    Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
    Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
    BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
    Zou Y; Wang F; Liu FY; Huang MZ; Li W; Yuan XQ; Huang OP; He M
    Gene; 2013 Nov; 531(1):112-6. PubMed ID: 24001777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
    Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
    Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
    McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
    McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
    J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial cancer with a POLE mutation progresses frequently through the type I pathway despite its high-grade endometrioid morphology: a cohort study at a single institution in Japan.
    Monsur M; Yamaguchi M; Tashiro H; Yoshinobu K; Saito F; Erdenebaatar C; Li C; Iwagoi Y; Ohba T; Iyama KI; Katabuchi H
    Med Mol Morphol; 2021 Jun; 54(2):133-145. PubMed ID: 33399963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
    Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
    Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
    Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
    Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.
    Matsumoto T; Yamazaki M; Takahashi H; Kajita S; Suzuki E; Tsuruta T; Saegusa M
    Am J Clin Pathol; 2015 Sep; 144(3):452-63. PubMed ID: 26276776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach.
    Wu RC; Veras E; Lin J; Gerry E; Bahadirli-Talbott A; Baras A; Ayhan A; Shih IM; Wang TL
    Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 29162652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma.
    Geyer FC; Pareja F; Burke KA; Schultheis AM; Hussein YR; Ye J; De Filippo MR; Marchio C; Macedo GS; Piscuoglio S; Lim RS; Toy E; Murali R; Jungbluth AA; Reis-Filho JS; Soslow RA; Weigelt B
    Histopathology; 2017 Sep; 71(3):480-487. PubMed ID: 28417598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of
    Zou Y; Huang MZ; Liu FY; Yang BC; Wang LQ; Wang F; Yu XH; Wan L; Wan XD; Xu XY; Li W; Huang OP; He M
    Biomed Rep; 2015 Jan; 3(1):33-37. PubMed ID: 25469243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma.
    Cao SN; Chang KH; Luthra R; Liu J
    Mod Pathol; 2003 Oct; 16(10):1048-52. PubMed ID: 14559989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
    Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.